Analysis of Impurities in New-generation Antidepressants by Prominence-i

Introduction

Pharmaceutical companies in Japan are under notification by the Ministry of Health, Labour and Welfare to carefully consider the administration of the new-generation antidepressant drugs that have been on the market since 1999 in Japan to patients under the age of 181). Further, to ensure the properties and suitability of these drugs, they are listed in the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP). The new Prominence-i integrated high-performance liquid chromatograph features separation compatibility with the systems of other companies. Further, use of the delay volume-compatible system kit option provides separation compatibility with the previous LC-2010 model, thereby permitting the smooth transfer of methods from the currently used instrument. Here, using the new Prominence-i integrated high- performance liquid chromatograph, we introduce an example of analysis of compounds related to the abovementioned new-generation antidepressants.

August 21, 2014 GMT